{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:51:05Z","timestamp":1790142665949,"version":"4.0.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Rationale<\/jats:title>\n            <jats:p>Anxiety is a chronic severe psychiatric disorder. In a series of studies, the implication of the gaseous molecule nitric oxide (NO) in anxiety has been evidenced. Further, the outcome of preclinical research suggests that different NO donors, including sodium nitroprusside (SNP), have expressed an anxiolytic profile revealed in animal models of anxiety. Regardless of this, it is not yet clarified the mechanism(s) of action by which SNP induces its beneficial effects on anxiety. In this context, it has been hypothesized that these effects might be attributed to a potential interaction of this NO donor with the GABA type A and the 5-HT<jats:sub>1A<\/jats:sub> serotonergic receptors.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Objectives<\/jats:title>\n            <jats:p>The current study was designed to investigate this issue in the male rat.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>To this end, the light\/dark box and the open field tests were utilized.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>SNP (1\u00a0mg\/kg, i.p.) applied acutely induced an anti-anxiety-like effect evidenced either in the light\/dark box or in the open field test. Either the GABA<jats:sub>A<\/jats:sub> receptor antagonist flumazenil (10\u00a0mg\/kg, i.p.) or the 5-HT<jats:sub>1A<\/jats:sub> serotonin receptor agonist 8-OH-DPAT (0.25\u00a0mg\/kg, i.p.) suppressed the above reported anxiolytic effects of SNP.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The results here reported propose a functional interaction between SNP with the GABAergic and the serotonergic systems on anxiety and thus, might offer a plausible explanation for SNP\u2019s anxiolytic effects.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00213-025-06759-1","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T04:39:22Z","timestamp":1739853562000},"page":"793-801","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Involvement of the GABAergic and the serotonergic systems in the anxiolytic effects expressed by the nitric oxide (NO) donor sodium nitroprusside (SNP) in the male rat"],"prefix":"10.1007","volume":"242","author":[{"given":"Maria Anastasia","family":"Parlantza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Pitsikas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,18]]},"reference":[{"key":"6759_CR1","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.neuropharm.2013.05.030","volume":"73","author":"AE Arran","year":"2013","unstructured":"Arran AE, Coburn E, Jacobsen J, Kuhn CM (2013) Lower anxiogenic effects of serotonin agonists are associated with lower activation of amygdala and lateral orbital cortex in adolescent male rats. Neuropharmacology 73:359\u2013367","journal-title":"Neuropharmacology"},{"key":"6759_CR2","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/0091-3057(87)90006-2","volume":"28","author":"C Belzung","year":"1987","unstructured":"Belzung C, Misslin R, Vogel E, Dodd RH, Chapouthier G (1987) Anxiogenic effects of methyl-carboline-carboxylate in a light\/dark choice situation. Pharmacol Biochem Behav 28:29\u201333","journal-title":"Pharmacol Biochem Behav"},{"key":"6759_CR3","doi-asserted-by":"crossref","unstructured":"Bisset WL, Butler AR, Glidewell C, Reglinski J (1981) Sodium nitroprusside and cyanide release Reasons for re-appraisal. Br J Anesthesiol 53:1015\u20131018","DOI":"10.1093\/bja\/53.10.1015"},{"key":"6759_CR5","doi-asserted-by":"crossref","unstructured":"Bjork L, Frederiksson A, Hacksell U, Lewander T (1992) Effects of (R)-8-OHDPAT and the enantiomers of UH-301 on motor activities in the rat: Antagonism of (R)-8-OH-DPAT-induced effects. Eur Neuropharmacol 2:141\u2013147","DOI":"10.1016\/0924-977X(92)90024-3"},{"key":"6759_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.psychres.2013.07.030","volume":"210","author":"RJ Braga","year":"2013","unstructured":"Braga RJ, Reynolds GP, Siris SG (2013) Anxiety comorbidity in schizophrenia. Psychiatry Res 210:1\u20137","journal-title":"Psychiatry Res"},{"key":"6759_CR8","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/0896-6273(91)90374-9","volume":"7","author":"DS Bredt","year":"1991","unstructured":"Bredt DS, Glatt CE, Hwang PM, Fotuhi M, Dawson TM, Snyder SH (1991) Nitric oxide synthase protein and mRNA are discretely localized in neuronal populations of the mammalian CNS together with NADPH diaphorase. Neuron 7:615\u2013624","journal-title":"Neuron"},{"key":"6759_CR9","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1046\/j.1365-2826.2001.00683.x","volume":"13","author":"H Castel","year":"2001","unstructured":"Castel H, Vaudry H (2001) Nitric oxide directly activates GABAA receptor function through a cGMP\/protein kinase-independent pathway in frog pituitary melanotrophs. J Neuroendocrinol 13:695\u2013705","journal-title":"J Neuroendocrinol"},{"key":"6759_CR10","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.yhbeh.2003.02.002","volume":"44","author":"S Chiavegatto","year":"2003","unstructured":"Chiavegatto S, Nelson RJ (2003) Interaction of nitric oxide and serotonin in aggressive behavior. Horm Behav 44:233\u2013241","journal-title":"Horm Behav"},{"key":"6759_CR11","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/0091-3057(80)90067-2","volume":"13","author":"JN Crawley","year":"1980","unstructured":"Crawley JN, Goodwin FK (1980) Preliminary report of a simple animal behavior for the anxiolytic effect of benzodiazepines. Pharmacol Biochem Behav 13:167\u2013170","journal-title":"Pharmacol Biochem Behav"},{"key":"6759_CR12","doi-asserted-by":"crossref","unstructured":"Cryan JF, Sweeney FF (2011) The age of anxiety. role of animal models of anxiolytic action in drug discovery Br J Pharmacol 164:1129\u20131161","DOI":"10.1111\/j.1476-5381.2011.01362.x"},{"key":"6759_CR15","doi-asserted-by":"publisher","first-page":"5147","DOI":"10.1523\/JNEUROSCI.14-09-05147.1994","volume":"14","author":"TM Dawson","year":"1994","unstructured":"Dawson TM, Snyder SH (1994) Gases as biological messengers: nitric oxide and carbon monoxide in the brain. J Neurosci 14:5147\u20135159","journal-title":"J Neurosci"},{"key":"6759_CR14","doi-asserted-by":"publisher","first-page":"7797","DOI":"10.1073\/pnas.88.17.7797","volume":"88","author":"TM Dawson","year":"1991","unstructured":"Dawson TM, Bredt DS, Fotuhi M, Hwang PM, Snyder SH (1991) Nitric oxide synthase and neuronal NADPH diaphorase are identical in brain and peripheral tissues. Proc Natl Acad Sci USA 88:7797\u20137801","journal-title":"Proc Natl Acad Sci USA"},{"key":"6759_CR16","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S0149-7634(98)00026-8","volume":"23","author":"RMM De Almeida","year":"1998","unstructured":"De Almeida RMM, Giovenardi M, Charchat H, Lucion AB (1998) 8-OH-DPAT in the medial raphe decreases while in the medial septal area it may increase anxiety in female rats. Neurosci Biobehav Rev 23:259\u2013264","journal-title":"Neurosci Biobehav Rev"},{"key":"6759_CR17","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1038\/sj.npp.1300437","volume":"29","author":"GS Elfline","year":"2004","unstructured":"Elfline GS, Branda EM, Babich M, Quock RM (2004) Antagonism by NOS inhibition of the behavioural effects of benzodiazepine and GABAA receptor agonists in the mouse elevated plus-maze. Neuropsychopharmacology 29:1419\u20131425","journal-title":"Neuropsychopharmacology"},{"key":"6759_CR18","doi-asserted-by":"crossref","unstructured":"Engin E, Treit D (2008) The effects of intra-cerebral drug infusions on animals\u2019 unconditioned fear reactions: a systematic review. Prog Neuropsychopharmacol Biol Psychiatry 32:1399\u20131419","DOI":"10.1016\/j.pnpbp.2008.03.020"},{"key":"6759_CR20","doi-asserted-by":"publisher","first-page":"4810","DOI":"10.1523\/JNEUROSCI.16-15-04810.1996","volume":"16","author":"SE File","year":"1996","unstructured":"File SE, Gonzalez LE, Andrews N (1996) Comparative study of pre- and postsynaptic 5-HT1A receptor modulation of anxiety in two ethological animal tests. J Neurosci 16:4810\u20134815","journal-title":"J Neurosci"},{"key":"6759_CR21","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/0166-2236(91)90022-M","volume":"14","author":"J Garthwaite","year":"1991","unstructured":"Garthwaite J (1991) Glutamate nitric oxide and cell-cell signalling in the nervous system. Trends Neurosci 14:60\u201367","journal-title":"Trends Neurosci"},{"key":"6759_CR22","first-page":"28","volume":"64","author":"JM Gorman","year":"2003","unstructured":"Gorman JM (2003) New molecule targets for antianxiety interventions. J Clin Psychiatry 64:28\u201335","journal-title":"J Clin Psychiatry"},{"key":"6759_CR23","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ejphar.2013.05.048","volume":"715","author":"V Grivas","year":"2013","unstructured":"Grivas V, Markou A, Pitsikas N (2013) The metabotropic glutamate 2\/3 receptor agonist LY379268 induces anxiety-like behavior at the highest dose tested in two rat models of anxiety. Eur J Pharmacol 715:105\u2013110","journal-title":"Eur J Pharmacol"},{"key":"6759_CR24","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/j.neubiorev.2005.03.026","volume":"29","author":"FD Guimaraes","year":"2005","unstructured":"Guimaraes FD, Beijamini V, Moreira FA, Aguiar DC, de Lucca ACB (2005) Role of nitric oxide in brain regions related to defensive reactions. Neurosci Biobehav Rev 29:1313\u20131322","journal-title":"Neurosci Biobehav Rev"},{"key":"6759_CR25","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1001\/jamapsychiatry.2013.1292","volume":"70","author":"JEC Hallak","year":"2013","unstructured":"Hallak JEC, Maia-de-Oliveira JP, Abrao J, Evora PR, Zuardi AW, Crippa JAS, Belmonte-de-Abreu P, Baker GB, Dursun SM (2013) Rapid improvement of acute schizophrenia symptoms after intravenous sodium nitroprusside. A randomized, double-blind, placebo-controlled trial. JAMA Psychiatry 70:668\u2013676","journal-title":"JAMA Psychiatry"},{"key":"6759_CR26","doi-asserted-by":"crossref","unstructured":"Hammer MB, Robert S, Fruech BS (2004) Treatment-resistant posttraumatic stress disorder Strategies for intervention. CNS Spectr 9:740\u2013752","DOI":"10.1017\/S1092852900022380"},{"key":"6759_CR28","first-page":"48","volume":"4","author":"RL Holt","year":"2007","unstructured":"Holt RL, Bruce Lydiard R (2007) Management of treatment-resistant panic disorder. Psychiatry 4:48\u201359","journal-title":"Psychiatry"},{"key":"6759_CR29","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.pbb.2006.05.021","volume":"84","author":"G Imre","year":"2006","unstructured":"Imre G, Salomons A, Jongsma M, Fokkema DS, Den Boer JA, Ter Horst GJ (2006) Effects of the mGluR2\/3 agonist LY379268 on ketamine-evoked behaviours and neurochemical changes in the dentate gyrus of the rat. Pharmacol Biochem Behav 84:392\u2013399","journal-title":"Pharmacol Biochem Behav"},{"key":"6759_CR30","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/0014-2999(89)90508-6","volume":"173","author":"OH Kalkman","year":"1989","unstructured":"Kalkman OH (1989) \u03b2-adrenoceptor blockade in rats enhances the ambulation induced by 5-HTIA receptor agonists. Eur J Pharmacol 173:121\u2013125","journal-title":"Eur J Pharmacol"},{"key":"6759_CR31","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.pbb.2015.09.004","volume":"138","author":"T Kalouda","year":"2015","unstructured":"Kalouda T, Pitsikas N (2015) The nitric oxide donor molsidomine induces anxiolytic-like behaviour in two different rat models of anxiety. Pharmacol Biochem Behav 138:111\u2013116","journal-title":"Pharmacol Biochem Behav"},{"key":"6759_CR32","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/mpr.1359","volume":"21","author":"RC Kessler","year":"2012","unstructured":"Kessler RC, Petukhova M, Sampson A, Zaslavsky AM, Wittchen HU (2012) Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. Int J Methods Psychiatr Res 21:169\u2013184","journal-title":"Int J Methods Psychiatr Res"},{"key":"6759_CR33","volume-title":"Experimental design: procedures for the behavioral science","author":"RE Kirk","year":"1968","unstructured":"Kirk RE (1968) Experimental design: procedures for the behavioral science. Brooks\/Cole, Belmont, CA, USA"},{"key":"6759_CR34","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1007\/BF00510138","volume":"320","author":"VAW Kreye","year":"1982","unstructured":"Kreye VAW, Reske SN (1982) Possible site of the in vivo disposition of sodium nitroprusside in the rat. Naunyn-Schmiedeberg\u2019s Arch Pharmacol 320:260\u2013265","journal-title":"Naunyn-Schmiedeberg\u2019s Arch Pharmacol"},{"key":"6759_CR35","doi-asserted-by":"publisher","first-page":"3348","DOI":"10.1523\/JNEUROSCI.2211-19.2020","volume":"40","author":"EA Larson","year":"2020","unstructured":"Larson EA, Accardi MV, D\u2019Antoni M, Karimi B, Siddiqui TJ, Bowie D (2020) Nitric oxide signaling strengthens inhibitory synapses of cerebellar molecular layer interneurons through a GABARAP-dependent mechanism. J Neurosci 40:3348\u20133359","journal-title":"J Neurosci"},{"key":"6759_CR36","first-page":"481","volume":"3","author":"I Lucki","year":"1990","unstructured":"Lucki I, Wieland S (1990) 5-Hydroxytryptamine1A receptors and behavioral responses. Neuropsychopharmacology 3:481\u2013493","journal-title":"Neuropsychopharmacology"},{"key":"6759_CR37","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/S0028-3908(03)00046-7","volume":"44","author":"CP M\u00fcller","year":"2003","unstructured":"M\u00fcller CP, Carey RJ, Salloum JB, Huston JP (2003) Serotonin1A-receptor agonism attenuates the cocaine-induced increase in serotonin levels in the hippocampus and nucleus accumbens but potentiates hyperlocomotion: an in vivo microdialysis study. Neuropharmacology 44:592\u2013603","journal-title":"Neuropharmacology"},{"key":"6759_CR38","doi-asserted-by":"publisher","first-page":"107848","DOI":"10.1016\/j.nlm.2023.107848","volume":"205","author":"S Nicolaus","year":"2023","unstructured":"Nicolaus S, Chao OY, Beu M, Henke J, Antke C, Wang AL, Fazari B, Mamlins E, Huston JP, Giesel FL (2023) The 5-HT1A receptor agonist 8-OH-DPAT modulates motor\/exploratory activity, recognition memory and dopamine transporter binding in the dorsal and ventral striatum. Neurobiol Learn Mem 205:107848","journal-title":"Neurobiol Learn Mem"},{"key":"6759_CR39","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.niox.2017.05.002","volume":"69","author":"MA Orfanidou","year":"2017","unstructured":"Orfanidou MA, Lafioniatis A, Trevlopoulou A, Touzlatzi N, Pitsikas N (2017) Acute and repeated exposure with the nitric oxide (NO) donor sodium nitroprusside (SNP) differentially modulate responses in a rat model of anxiety. Nitric Oxide 69:56\u201360","journal-title":"Nitric Oxide"},{"key":"6759_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.niox.2020.03.005","volume":"99","author":"A Papageorgoulis","year":"2020","unstructured":"Papageorgoulis A, Fallon P, Mpalantes N, Papageorgouli D, Pitsikas N (2020) Repeated but not acute exposure with a low dose range of the nitric oxide (NO) donor sodium nitroprusside (SNP) induces anxiolytic-like behaviour in a dose-independent manner in two different rat models of anxiety. Nitric Oxide 99:1\u20136","journal-title":"Nitric Oxide"},{"key":"6759_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.niox.2022.09.001","volume":"129","author":"E Peristeri","year":"2022","unstructured":"Peristeri E, Pitsikas N (2022) Effects of low doses of different nitric oxide (NO) donors in rat models of obsessive-compulsive disorder (OCD) and posttraumatic stress disorder (PTSD). Nitric Oxide 129:1\u20137","journal-title":"Nitric Oxide"},{"key":"6759_CR43","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.niox.2018.04.002","volume":"77","author":"N Pitsikas","year":"2018","unstructured":"Pitsikas N (2018) The role of nitric oxide (NO) donors in anxiety. Lights and shadows. Nitric Oxide 77:6\u201311","journal-title":"Nitric Oxide"},{"key":"6759_CR44","doi-asserted-by":"publisher","first-page":"5647","DOI":"10.3390\/molecules25235647","volume":"25","author":"N Pitsikas","year":"2020","unstructured":"Pitsikas N, Tarantilis PA (2020) The GABAA-benzodiazepine receptor antagonist flumazenil abolishes the anxiolytic effects of the active constituents of Crocus sativus L., crocins in rats. Molecules 25:5647","journal-title":"Molecules"},{"key":"6759_CR42","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.bbr.2004.11.007","volume":"159","author":"N Pitsikas","year":"2005","unstructured":"Pitsikas N, Tsitsirigou S, Zisopoulou S, Sakellaridis N (2005) The 5-HT1A receptor and recognition memory. Possible modulation of its behavioral effects by the nitrergic system. Behav Brain Res 159:287\u2013293","journal-title":"Behav Brain Res"},{"key":"6759_CR45","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0301-0082(00)00044-7","volume":"64","author":"H Prast","year":"2001","unstructured":"Prast H, Philippu A (2001) Nitric oxide as modulator of neuronal function. Progr Neurobiol 64:51\u201368","journal-title":"Progr Neurobiol"},{"key":"6759_CR46","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0014-2999(03)01272-X","volume":"463","author":"L Prut","year":"2003","unstructured":"Prut L, Belzung C (2003) The open field as a paradigm to measure the effects of drugs on anxiety-like behaviours: a review. Eur J Pharmacol 463:3\u201333","journal-title":"Eur J Pharmacol"},{"key":"6759_CR47","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.3390\/ijms21072597","volume":"21","author":"L Rombola\u2019","year":"2020","unstructured":"Rombola\u2019 L, Scuteri D, Watanabe C, Sakurada S, Hamamura K, Sakurada T, Tonin P, Corasaniti MT, Bagetta G, Morrone LA (2020) Role of the 5-HT1A receptor in the anxiolytic-relaxant effects of bergamol essential oil in rodent. Int J Mol Sci 21:2597","journal-title":"Int J Mol Sci"},{"key":"6759_CR48","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S0014-2999(97)01503-3","volume":"342","author":"C Schmidt-Mutter","year":"1998","unstructured":"Schmidt-Mutter C, Pain L, Sandner G, Gobaille S, Maitre M (1998) The anxiolytic effect of g-hydroxybutyrate in the elevated plus maze is reversed by the benzodiazepine receptor antagonist, flumazenil. Eu J Pharmacol 342:21\u201327","journal-title":"Eu J Pharmacol"},{"key":"6759_CR49","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/0006-8993(93)90742-6","volume":"627","author":"A Shekhar","year":"1993","unstructured":"Shekhar A (1993) GABA receptors in the region of the dorsomedial hypothalamus of rats mediate anxiety in the elevated plus-maze test. I. behavioral measures. Brain Res 627:9\u201316","journal-title":"Brain Res"},{"key":"6759_CR50","unstructured":"Steimer T (2018) The biology of fear-and anxiety-related behaviors. Dialogues Clin Neurosci 28:123\u2013137"},{"key":"6759_CR52","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1017\/S1092852900022392","volume":"9","author":"M Van Ameringen","year":"2004","unstructured":"Van Ameringen M, Mancini C, Pipe B, Bennett M (2004) Optimizing treatment in social phobia: a review of treatment resistance. CNS Spectr 9:753\u2013762","journal-title":"CNS Spectr"},{"key":"6759_CR53","first-page":"43","volume-title":"Nitric oxide in the nervous system","author":"PD Varner","year":"1995","unstructured":"Varner PD, Beckman JS (1995) Nitric oxide toxicity in neuronal injury and degeneration. In: Vincent S (ed) Nitric oxide in the nervous system. Academic, San Diego, pp 43\u201350"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-025-06759-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00213-025-06759-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-025-06759-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T05:01:58Z","timestamp":1747458118000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00213-025-06759-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,18]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["6759"],"URL":"https:\/\/doi.org\/10.1007\/s00213-025-06759-1","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,18]]},"assertion":[{"value":"21 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The procedures that involved animals and their care were conducted in accordance with international guidelines and national (Animal Act, P.D. 160\/91) and international laws and policies (EU Directive 2010\/63). Experiments were approved by the local committee (Prefecture of Larissa, Greece, protocol number 58379\/2023). Every effort was made to minimize the number of animals used and their suffering.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}